CRISPR Therapeutics AG
NasdaqGM:CRSP
Sector
Location
Market Cap
USD 5.15 B
Share Price
USD 56.60
Avg Daily Volume
3,157,840
Change (1 day)
2.15%
Change (1 year)
20.66%
Change (YTD)
43.80%
CRISPR Therapeutics AG Income Statement 2015 - 2025
This table shows the Income Statement for CRISPR Therapeutics AG going from 2015 until 2025. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement
| Annual data in millions of USD, except per share data | Trend |
|---|
Competitors
Eli Lilly and Company
USD 639.43
LLY
+4.21
0.66%
AbbVie Inc.
USD 198.64
ABBV
-0.06
-0.03%
Roche Holding AG
USD 320.12
RO.SW
+2.62
0.83%
AstraZeneca PLC
USD 150.15
AZN.L
-2.01
-1.32%
Novartis AG
USD 119.03
NOVN.SW
+1.05
0.89%
Novo Nordisk A/S
USD 50.00
NOVO-B.CO
-0.09
-0.18%
Merck & Co., Inc.
USD 80.30
MRK
+0.27
0.34%
Thermo Fisher Scientific Inc.
USD 477.41
TMO
+15.02
3.25%
Amgen Inc.
USD 284.98
AMGN
-0.11
-0.04%
Gilead Sciences, Inc.
USD 120.02
GILD
-0.45
-0.37%
Pfizer Inc.
USD 24.65
PFE
+0.07
0.29%
Sanofi
USD 95.31
SAN.PA
+0.83
0.88%
Vertex Pharmaceuticals Incorporated
USD 387.77
VRTX
+13.31
3.55%
Bristol-Myers Squibb Company
USD 46.55
BMY
+0.62
1.35%
Chugai Pharmaceutical Co., Ltd.
USD 42.73
4519.T
+0.95
2.28%